Point-solution use for GLP-1 management nearly triples in two years

A new industry analysis shows payer and employer use of third-party point solutions to manage GLP-1 agonist prescriptions (e.g., Wegovy, Zepbound) has nearly tripled since 2024. These vendors typically enforce strict prior authorization protocols, step therapy, and lifestyle monitoring requirements that go beyond standard pharmacy benefit management. The shift means practices prescribing these drugs are increasingly interacting with a specialized intermediary, not the patient's primary medical or pharmacy benefit manager. This fragments the authorization process and can introduce new documentation hurdles. If your practice prescribes GLP-1s, prepare for more encounters with named vendors like Hello Alpha, Form Health, or Sequence, and verify whether their requirements are in addition to or in place of the primary payer's PA rules.